title: [The effectiveness of pioglitazone in the treatment of patients with coronary heart disease on the background of metabolic syndrome].
abstract: We investigated the effectiveness of pioglitazone in the treatment of patients with coronary heart disease in combination with MS. In the conduct of research revealed that the addition to standard therapy in patients with coronary heart disease on the background of metabolic syndrome pioglitazone led to a reliable slight decrease in body weight, BMI, hip circumference, waist their relationship. Receiving pioglitazone also significantly reduces the concentration of immunoreactive insulin and blood glucose levels, significantly altered lipid metabolism, which generally leads to a lower level of systemic inflammation, metabolism and reduces the severity of insulin resistance. This allows you to recommend the inclusion of pioglitazone in complex coronary heart disease and metabolic syndrome.
authors.forename: N I
authors.initials: NI
authors.lastname: Vinnik
authors.forename: L A
authors.initials: LA
authors.lastname: Kutsenko
authors.forename: N L
authors.initials: NL
authors.lastname: Kutsenko
authors.forename: I L
authors.initials: IL
authors.lastname: Solokhina
authors.forename: M V
authors.initials: MV
authors.lastname: Mikitiuk
authors.forename: T V
authors.initials: TV
authors.lastname: Mamontova
authors.forename: I P
authors.initials: IP
authors.lastname: Kaĭdashev
mesh_terms: D000368:Aged; D017311:Amlodipine / Q000008:administration & dosage / Q000627:therapeutic use; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D000069059:Atorvastatin; D017298:Bisoprolol / Q000008:administration & dosage / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D002097:C-Reactive Protein / Q000032:analysis / Q000276:immunology; D003327:Coronary Disease / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D007548:Isosorbide Dinitrate / Q000008:administration & dosage / Q000627:therapeutic use; D050356:Lipid Metabolism / Q000187:drug effects; D015227:Lipid Peroxidation / Q000187:drug effects; D024821:Metabolic Syndrome / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D008875:Middle Aged; D000077205:Pioglitazone; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000008:administration & dosage* / Q000627:therapeutic use; D049629:Waist-Hip Ratio
chemical_list: D001786:Blood Glucose; D006538:Heptanoic Acids; D007004:Hypoglycemic Agents; D007328:Insulin; D011758:Pyrroles; D045162:Thiazolidinediones; D017311:Amlodipine; D002097:C-Reactive Protein; D000069059:Atorvastatin; D007548:Isosorbide Dinitrate; D001241:Aspirin; D000077205:Pioglitazone; D017298:Bisoprolol